Literature DB >> 3360658

Heterogeneity of radiation response of a parent human epidermoid carcinoma cell line and four clones.

R R Weichselbaum1, M A Beckett, W Dahlberg, A Dritschilo.   

Abstract

We examined the radiobiological parameters of a parent tumor cell line and four tumor clones of a human skin squamous cell carcinoma. The parent line and all clones have a tumor morphology, aneuploid karyotype, and the ability to passage infinitely in vitro. The parent cell line and three of four clones formed tumors in nude mice. The parent line, SCC-12, has a D0 of 1.59 Gy and an n of 7.5. In the four clones, D0 ranges from 1.31 Gy to 2.66 Gy and n ranges from 2.1 to 22.8. Potentially lethal damage repair (PLDR) following 11 Gy ranges from 1.7 to 13.1, at 24 hours, however PLDR following equitoxic doses of radiation is similar. The mean inactivation dose value (D) in the parent tumor cell line is 3.48 and ranges from 3.31 to 4.17 in the tumor clones. Radiobiological interpretation of heterogeneity may complicate predictive assays for clinical radiotherapy.

Entities:  

Mesh:

Year:  1988        PMID: 3360658     DOI: 10.1016/0360-3016(88)90013-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Cytogenetic analyses of a murine carcinoma cell line and six metastatic derivatives with different degrees of radioresistability.

Authors:  R J Jamasbi; M Q Ye; T M Norvell
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-02       Impact factor: 2.416

2.  Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest.

Authors:  X Wang; C H McGowan; M Zhao; L He; J S Downey; C Fearns; Y Wang; S Huang; J Han
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

3.  DNA double-strand break rejoining rates, inherent radiation sensitivity and human tumour response to radiotherapy.

Authors:  J L Schwartz; R Mustafi; M A Beckett; R R Weichselbaum
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.